ct26 mouse colon cancer cell line (ATCC)
ATCC is a verified supplier 
ATCC manufactures this product 
99
Structured Review
ATCC
ct26 mouse colon cancer cell line
Ct26 Mouse Colon Cancer Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 3128 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ct26+mouse+colon+cancer+cell+line/CT26%2EWT/pm41935049-226-10-25
Average 99 stars, based on 3128 article reviews
Ct26 Mouse Colon Cancer Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 3128 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ct26+mouse+colon+cancer+cell+line/CT26%2EWT/pm41935049-226-10-25
Average 99 stars, based on 3128 article reviews
ct26 mouse colon cancer cell line - by Bioz Stars,
2026-09
99/100 stars
Images
Related Articles
other:Article Title: The key role of calreticulin in immunomodulation induced by chemotherapeutic agents. Article Snippet: Background It has recently been shown that certain chemotherapeutic agents can improve host immune responses.. The present study aimed to demonstrate the mechanism by which chemotherapeutic agents modify the tumor microenvironment and induce tumor-specific immune responses.. Methods Three mouse cancer cell lines [CT26 mouse colon cancer cells, B16 melanoma cells and Lewis lung carcinoma (LLC)], 5 human carcinoma cell lines (human esophageal squamous cell carcinoma cell lines TE8 and HEC46 and the human pancreatic carcinoma cell lines PK9, AsPC-1 and SUIT-2) and 5 chemotherapeutic agents [mitoxantrone (MIT), mitomycin C(MMC), 5-fluorouracil (5FU), camptothecin (CPT-11) and cisplatin (CDDP)] that are frequently used in a clinical setting for cancer treatment were utilized to investigate the surface expression level of calreticulin and HLA class I after exposure to chemotherapeutic agents. Cell Culture:Article Title: A NanoFlare-Based Strategy for In Situ Tumor Margin Demarcation and Neoadjuvant Gene/Photothermal Therapy. Article Snippet: R. Yan, J. Rao, Y. Liu, Prof. L. Zhang, Prof. Y.-Q.. Li State Key Laboratory of Radiation Medicine and Protection School of Radiation Medicine and Protection Collaborative Innovation Center of Radiological Medicine of Jiangsu Higher Education Institutions Soochow University Suzhou 215123, China E-mail: lyq@suda.edu.cn Dr. J. Chen Suzhou Hospital Affiliated to Nanjing Medical University Suzhou 215002, China Multiple Displacement Amplification:Article Title: A NanoFlare-Based Strategy for In Situ Tumor Margin Demarcation and Neoadjuvant Gene/Photothermal Therapy. Article Snippet: R. Yan, J. Rao, Y. Liu, Prof. L. Zhang, Prof. Y.-Q.. Li State Key Laboratory of Radiation Medicine and Protection School of Radiation Medicine and Protection Collaborative Innovation Center of Radiological Medicine of Jiangsu Higher Education Institutions Soochow University Suzhou 215123, China E-mail: lyq@suda.edu.cn Dr. J. Chen Suzhou Hospital Affiliated to Nanjing Medical University Suzhou 215002, China Knockdown:Article Title: Cell surface–tethered IL-12 repolarizes the tumor immune microenvironment to enhance the efficacy of adoptive T cell therapy Article Snippet: .. The MART-1–positive, HLA-A*02:01–positive human melanoma cell line SK-MEL-5; the MART-1–negative, HLA-A*02:01–positive human melanoma cell line A375; B16-F10 mouse melanoma cell line; Jurkat Clone E6-1 cell line; Jurkat CD45 knockdown cell line J45.0 l; and |
![Combination CTLA-4 with PDL1 peptide vaccine in <t>CT26-BALB/c</t> tumor model. A, Six- to eight-week-old BALB/c mice were vaccinated with combination peptides as designed [MVF-PDL1 (130) with MVF-CTLA-4 (130)] for 3-week interval. A measure of 0.1 mg of each peptide cancer vaccine mixed with ISA 720 (1:1) used per mouse. Mice were boosted with the designed doses for every 3-week intervals. Blood was collected weekly for monitoring antibody titers. After 2 weeks of the third time immunization (3Y), mice were challenged with 2 × 10 5 per mouse D2F2 tumor cells or 5 × 10 5 per mouse 4T1 tumor cells. After tumor challenge, in the positive control group, we treated the mice with anti-mouse antibodies 10F.9G2 plus 9H10 twice a week for up to 3 weeks, and the negative control group was treated with PBS. Tumor volume was calculated as follows: Tumor volume (LWW) = (length × width × width)/2. B, Immunogenicity of MVF-CTLA-4 plus MVF-PDL1 (130) peptides immunized BALB/c mice. Mice bleeds were collected weekly except the first collection was 3 weeks after primary immunization, and ELISA was used to detect antibody titers in sera; C, Antibody isotypes from mice bleed immunized with MVF-CTLA-4 (130) plus MVF-PDL1 (130) combination peptide vaccine. D, Tumor burden (LWW) by days in BALB/c mice of each treatment group (10 mice/group) and tumor models of both D2F2 and 4T1 BALB/c mammary carcinoma, and two-way ANOVA was used to analyze the whole curves of tumor growth. Tumor burden (LWW) analysis in BALB/c mice of each treatment group and tumor models, and one-way ANOVA was used to analyze at each time point as indicated at days 12 and 14 for the D2F2 model and days 9 and 12 for the 4T1 model after tumor challenging. E, The log-rank (Mantel–Cox) test was used to compare the survival curves. ns, no significant; *, P < 0.05; **, P < 0.01, all vs. with the PBS control group.](https://pub-med-central-images-cdn.bioz.com/pub_med_central_ids_ending_with_2803/pmc12402803/pmc12402803__mct-24-0908_f5.jpg)
![Combination CTLA-4 with PDL1 peptide vaccine in CT26-BALB/c tumor model. A, Six- to eight-week-old BALB/c mice (10 mice/group) were vaccinated with MVF peptides [MVF-CTLA-4 (59) or (130) with MVF-PDL1 (36) or (130)] as indicated for 3-week interval. Each peptide cancer vaccine 100 μg mixed with ISA 720 (1:1) was immunized per mouse. Mice were boosted with the designed doses, and bleeds were collected weekly for monitoring antibody titers. After 2 weeks of the third time immunization (3Y), mice were challenged with 1 × 10 5 CT26 tumor cells on day 0. The tumor growth checked daily, especially 7 days after challenging, and tumor size was measured using calipers. For the positive control group, we treated the mice with anti-mouse CTLA-4 antibody (clone 9H10) plus anti-mouse PDL1 antibody (10F.9G2) twice a week for up to 3 weeks, whereas the negative control group was treated with PBS. B, Immunogenicity of combination MVF-CTLA-4 with MVF-PDL1 peptides immunized BALB/c mice. Mice bleeds were collected weekly except the first collection was 3 weeks after primary immunization, and ELISA was used to detect antibody titers in sera; C, Tumor burden (LWW) by days in BALB/c mice of each treatment group (10 mice/group) and tumor models, and two-way ANOVA was used to analyze the whole curves of tumor growth. Tumor burden (LWW) analysis in BALB/c mice of each treatment group and tumor models, and one-way ANOVA was used to analyze at each time point as indicated at days 14 and 16 after tumor challenging. D, The log-rank (Mantel–Cox) test was used to compare the survival curves. ns, no significant; *, P < 0.05; **, P < 0.01, all vs. with the PBS control group.](https://pub-med-central-images-cdn.bioz.com/pub_med_central_ids_ending_with_2803/pmc12402803/pmc12402803__mct-24-0908_f4.jpg)
![Combination CTLA-4 with PDL1 peptide vaccine in CT26-BALB/c tumor model. A, Six- to eight-week-old BALB/c mice were vaccinated with combination peptides as designed MVF-CTLA-4 (130) combination with PD1-Vaxx [MVF-PD1 (92)] for 3-week interval. A measure of 0.1 mg of each peptide cancer vaccine mixed with ISA 720 (1:1) used per mouse. Mice were boosted with the designed doses for every 3 weeks intervals. Blood was collected weekly for monitoring antibody titers. After 2 weeks of the third time immunization (3Y), mice were challenged with 1 × 10 5 CT26 per mouse, or 2 × 10 5 per mouse D2F2 tumor cells, or 5 × 10 5 per mouse 4T1 tumor cells. After tumor challenge, in the positive control group, we treated the mice with anti-mouse antibodies 9H10 plus 29F.1A12 twice a week for up to 3 weeks, and the negative control group was treated with PBS. Tumor volume was calculated as follows: Tumor volume (LWW) = (length × width × width)/2. B, Immunogenicity of MVF-CTLA-4 plus PD1-Vaxx peptides immunized BALB/c mice. Mice bleeds were collected weekly except the first collection was 3 weeks after primary immunization, and ELISA were used to detect antibody titers in sera. C, Antibody isotypes from mice bleed immunized with MVF-CTLA-4 (130) plus MVF-PD1 (92) combination peptide vaccine. D, Tumor burden (LWW) by days in BALB/c mice of each treatment group (10 mice/group) and tumor models of CT26, D2F2, and 4T1 BALB/c carcinoma, and two-way ANOVA was used to analyze the whole curves of tumor growth. Tumor burden (LWW) analysis in BALB/c mice of each treatment group and tumor models, and one-way ANOVA was used to analyze at each time point as indicated at days 9 and 12 for the CT26 model, days 12 and 14 for the D2F2 model, and days 9 and 12 for 4T1 model after tumor challenging. E, The log-rank (Mantel–Cox) test was used to compare the survival curves. ns, no significant; *, P < 0.05; **, P < 0.01, all vs. with the PBS control group.](https://pub-med-central-images-cdn.bioz.com/pub_med_central_ids_ending_with_2803/pmc12402803/pmc12402803__mct-24-0908_f6.jpg)